Tagged with BI

Singapore Martin Dewhurst of the Global Pharmaceuticals and Medical Products Practice at McKinsey & Company provides his view of the Asia Pacific Medtech Forum 2016 in Singapore and elaborates on the prominent trends for the industry in the region. What have been your first impressions of the MedTech Forum and your…

Singapore In an exclusive interview with Stephen Ooi, Senior Executive Advisor at Zimmer Biomet, he emphasizes the strategic benefits of the global merger between Zimmer and Biomet and how through leveraging their synergies, Zimmer Biomet will continue to raise the standards of quality and take an active role in bringing musculoskeletal…

Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development.  Switzerland of course has quite the reputation as a hub for biotech activity – how…

Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…

Switzerland Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region.   Since day one, Alexion’s mission has been to focus solely on discovering treatments for patients affected by these incredibly rare…

Mexico Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to further accelerate the growth and consolidate the strategic positioning of Shire, a company that now proudly stands out as the…

Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…

Switzerland Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s business and remains a key part of their DNA; and how a focus on patient centricity remains at the core…

Ireland Chairman for BioPharmaChemical Ireland and Leader of Pfizer’s two small molecule API manufacturing sites in Cork, Seamus Fives recounts his team’s efforts to avert the closure of the Little Island facility through improvements in operating efficiency, and discusses how Pfizer is re-equipping their small molecule facilities to fit the needs…

Ireland Darren Cunningham tells us the story behind Inflection Biosciences (and its name), the rationale of focusing on small molecule cancer treatments, his thoughts on the Irish biotech start-up scene, and his hopes for the company’s future development. Can you first provide an introduction to Inflection Biosciences to our international audience? “The Irish…

ITTM’s innovative co-founder Dr. Andreas Kremer reveals the steps his start-up is currently undertaking to restructure the world of BioIT and the presentation of medical information. Why did you personally decide a year and half ago that ITTM was going to be your next adventure, and what were your first…

Singapore The CEO of ASLAN Pharmaceuticals, Dr. Carl Firth discusses the implications surrounding the company’s imminent initial public offering on Taiwan’s stock exchange, while explaining how this move serves to position ASLAN as Singapore’s first local success story. Having just completed a pre-IPO financing round, it seems the company has many…